mainly renal (unchanged), exposure is increased in renal impairment – on average by four-fold in subjects with severe renal impairment (CrCl <30 ml/min)
Trimetazidine (IUPAC: 1-(2,3,4-trimethoxybenzyl)piperazine) is a drug sold under many brand names for angina pectoris (chest pain associated with impaired blood flow to the heart).[1] Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). It is an anti-ischemic (antianginal) metabolic agent of the fatty acid oxidation inhibitor class, meaning that it improves the heart muscle's ability to use glucose as a fuel by inhibiting its use of fatty acid metabolism. It has become controversial for its use as a performance-enhancing drug, with several scandals involving its use erupting at successive Olympic games.
Trimetazidine is usually prescribed as a long-term treatment of angina pectoris, and in some countries (including France) for tinnitus and dizziness. It is taken twice a day. In 2012, the European Medicines Agency (EMA) finished a review of benefits and risks of trimetazidine and recommended restricting use of trimetazidine-containing medicines to just as an additional treatment of angina pectoris in cases of inadequate control by or intolerance to first-line antianginal therapies.[2]
Controlled studies in angina patients have shown that trimetazidine increases coronary flow reserve (thereby delaying the onset of ischemia associated with exercise), limits rapid swings in blood pressure without any significant variations in heart rate, significantly decreases the frequency of angina attacks, and leads to a significant decrease in the use of nitrates.[citation needed]
However, a 2020 placebo-controlled, randomized trial in over 6000 patients who had recently had a percutaneous coronary intervention or heart surgery found that adding trimetazidine to typical anti-anginal therapies alone led to no significant difference in cardiac death, hospital admission for a cardiac event, recurrence or persistence of angina, or the need for repeat coronary angiography.[3] This study therefore calls into question the clinical utility of trimetazidine in the treatment of angina.
As of 2023, it is in clinical trials to determine if it is effective in treating bipolar depression.[6]
Use as a performance-enhancing drug
Although trimetazidine was already developed for medical use in the 1970s, it only became listed in the World Anti-Doping Agency (WADA) prohibited substances list under the category of "hormone and metabolic modulators" in 2014,[7][8] and its use is prohibited at all times "in- and out-of-competition."[9]
In 2014, Chinese Olympic champion swimmer Sun Yang tested positive for trimetazidine, which had been newly banned four months earlier and classified as a prohibited stimulant by WADA; Sun Yang and his doctor claim that they were not made aware of the changes to the use of the drug of which he was prescribed, and was consequently banned by the Chinese Swimming Association for three months.[10]
In January 2015, WADA reclassified and downgraded trimetazidine from a "stimulant" to a "modulator of cardiac metabolism."[11][12]
In 2018, U.S. swimmer Madisyn Cox was banned from competition for six months after a urine sample tested positive for trimetazidine. FINA initially reduced her suspension from four years to two years because of Cox's testimony that she did not knowingly ingest the drug.[13] Upon analysis of both opened and sealed bottles of Cooper Complete Elite Athletic multivitamins, the Court of Arbitration for Sport (CAS) determined that the multivitamins were the source, and reduced Cox's suspension to six months. The suspension expired on September 3, 2018.[14]
23 Chinese swimmers tested positive by China Anti-Doping Agency for the drug in 2021, and reported to WADA, this case was reviewed by WADA in June and July 2021. The United States Anti-Doping Agency (USADA) contacted WADA in 2020 (before the positive TMZ cases arose) and 2023 with respect to allegations (from an unspecified source) of doping cover-ups within Chinese swimming. These allegations were unsubstantiated and WADA advised that the threshold to open an investigation was not met. [15]
In February 2022, the medal ceremony for the figure skating team event at the Olympics originally scheduled for Tuesday, 8 February, was delayed over what International Olympic Committee (IOC) spokesperson Mark Adams described as a situation that required "legal consultation" with the International Skating Union (ISU).[16] Several media outlets reported on Wednesday that the issue was over a December 2021 test for trimetazidine by the Russian Olympic Committee's Kamila Valieva,[17][18] whose result was released on February 11. The results are pending investigation.[19] Valieva was cleared by the Russian Anti-Doping Agency (RUSADA) on February 9, a day after positive results of a test held in December 2021 were released. The IOC, WADA, and ISU appealed RUSADA's decision.[20] On February 14, the Court of Arbitration for Sport ruled that Valieva would be allowed to compete in the women's single event, deciding that preventing her from competing "would cause her irreparable harm in the circumstances", though her gold medal in the team event was still under consideration. The favorable decision from the court was made in part due to her age, as minor athletes are subject to different rules from adult athletes.[21][22]
The IOC announced that the medal ceremony would not take place until the investigation was over and there was a concrete decision whether to strip Russia of their medals.[23]
Popular Science published an overview of scientific research about the potential for the use of trimetazidine as a performance enhancing drug for athletes. The author of the article concluded in its headline that "there's no hard proof that it would improve a figure skater's performance". Scott Powers, a physiologist at the University of Florida who studies the effects of exercise on the heart explained how trimetazidine was included in WADA list. "I've been involved in roundtables with the International Olympic Committee, and I think their policy is: When in doubt, ban the drug," says Scott Powers. "I guess they're just trying to err on the possibility that this drug may be an ergogenic aid."[24] Doping expert Klaas Faber referred to "grossly inconsistent anti-doping rules" in Sun Yang's case. Faber has pointed out for years the necessity to establish thresholds for trimetazidine detected so as to avoid any inadvertent positive doping cases. Faber has detailed some of these observations published in the journal Science & Justice.[25][12]
On the efficacy of the drug on figure skating and Valieva in particular, heart expert Benjamin J. Levine, a professor of exercise science at the University of Texas Southwestern Medical School, said "The chance that trimetazidine would improve her performance, in my opinion, is zero. The heart has plenty of blood. And the heart is so good at using different fuels."[24][26]
Aaron Baggish, director of the Cardiovascular Performance Program at Massachusetts General Hospital said "In theory, trimetazidine could aid endurance athletes who have to generate high cardiac output, such as cyclists, rowers and long-distance runners, but would be unlikely to have a direct impact on a figure skater's performance, where there is less demand on the heart."[27]
Besides trimetazidine, Valieva also admitted taking hypoxen and L-carnitine supplements in her forms, neither of which is a banned substance; nevertheless, the combination of these two substances with trimetazidine raised suspicions over a potential deliberate attempt to enhance performance. Some experts believe that the combination of the three substances can reduce fatigue and increased endurance during intense exercises.[28]
Trimetazidine has been treated as a drug with a high safety and tolerability profile.[30]
Information is scarce about trimetazidine's effect on mortality, cardiovascular events, or quality of life. Long-term randomized, controlled trials comparing trimetazidine against standard antianginal agents using clinically important outcomes would be justifiable.[30] A 2013 international multicentre retrospective cohort study has indeed shown that in patients with heart failure of different etiologies the addition of trimetazidine on conventional optimal therapy can improve mortality and morbidity.[31]
The EMA recommends that doctors no longer prescribe trimetazidine for the treatment of patients with tinnitus, vertigo, or disturbances in vision.[2] The recent EMA evaluation also revealed rare cases (3.6/1,000,000 patient years) of parkinsonian (or extrapyramidal) symptoms (such as tremor, rigidity, akinesia, hypertonia), gait instability, restless leg syndrome, and other related movement disorders; most patients recovered within 4 months after treatment discontinuation, so doctors are advised not to prescribe the medicine either to patients with Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, or other related movement disorders, or to patients with severe renal impairment.[2]
Mechanism of action
The mechanism of action of trimetazidine involves its effect on cellular energy metabolism, specifically the metabolism of fatty acids and glucose.
One of the primary ways that cells generate energy is through the process of oxidation, where molecules such as fatty acids or glucose are broken down to produce ATP (adenosine triphosphate), the main energy currency of cells. In a healthy cell both fatty acids and glucose can be oxidized to produce ATP.
However, in certain situations such as ischemia (reduced blood flow) or hypoxia (reduced oxygen supply), the cell's ability to generate energy becomes compromised. In these conditions the cell may experience a shortage of oxygen, which is necessary for the complete oxidation of fatty acids. This can lead to a decrease in ATP production, affecting the cell's ability to maintain its normal functions.
Trimetazidine works by inhibiting a specific enzyme called long-chain 3-ketoacyl-CoA thiolase, which is involved in the beta-oxidation process of fatty acids. By blocking this enzyme, trimetazidine reduces the oxidation of fatty acids and promotes the oxidation of glucose instead. Glucose oxidation requires less oxygen consumption compared to the beta-oxidation of fatty acids.[32] Therefore, by enhancing glucose oxidation and reducing the reliance on fatty acid metabolism, trimetazidine helps optimize cellular energy production in conditions where oxygen supply is limited.
By preserving energy metabolism and promoting glucose oxidation, trimetazidine prevents a decrease in intracellular ATP levels. This is important because ATP is essential for various cellular processes, including the functioning of ionic pumps and the maintenance of transmembrane sodium-potassium flow. By ensuring adequate ATP levels, trimetazidine helps to maintain cellular homeostasis, or the balance of different ions and molecules within the cell.[33]
Related Research Articles
Coronary artery disease (CAD), also called coronary heart disease (CHD), ischemic heart disease (IHD), myocardial ischemia, or simply heart disease, involves the reduction of blood flow to the cardiac muscle due to build-up of atherosclerotic plaque in the arteries of the heart. It is the most common of the cardiovascular diseases. Types include stable angina, unstable angina, and myocardial infarction.
Angina, also known as angina pectoris, is chest pain or pressure, usually caused by insufficient blood flow to the heart muscle (myocardium). It is most commonly a symptom of coronary artery disease.
Variant angina, also known as Prinzmetal angina,vasospastic angina, angina inversa, coronary vessel spasm, or coronary artery vasospasm, is a syndrome typically consisting of angina. Variant angina differs from stable angina in that it commonly occurs in individuals who are at rest or even asleep, whereas stable angina is generally triggered by exertion or intense exercise. Variant angina is caused by vasospasm, a narrowing of the coronary arteries due to contraction of the heart's smooth muscle tissue in the vessel walls. In comparison, stable angina is caused by the permanent occlusion of these vessels by atherosclerosis, which is the buildup of fatty plaque and hardening of the arteries.
Competitors at the Olympic Games have used banned athletic performance-enhancing drugs.
Coronary vasospasm refers to when a coronary artery suddenly undergoes either complete or sub-total temporary occlusion.
GW501516 is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s. It entered into clinical development as a drug candidate for metabolic and cardiovascular diseases, but was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.
Meldonium is a limited-market pharmaceutical, developed in 1970 by Ivars Kalviņš at the USSR Latvia Institute of Organic Synthesis, and now manufactured by the Latvian pharmaceutical company Grindeks and several generic manufacturers. It is primarily distributed in Eastern European countries as an anti-ischemia medication.
Fatty acid oxidation inhibitors are a new potent class of drugs used in treatment of stable angina pectoris and an addition in treatment of chronic heart failure.
The swimming competitions at the 2020 Summer Olympics in Tokyo were due to take place from 25 July to 6 August 2020 at the Olympic Aquatics Centre. Due to the COVID-19 pandemic, the games were postponed to 2021. However, their official name remained 2020 Summer Olympics with swimming events set for 24 July–1 August 2021 and marathon swimming set for 4–5 August 2021.
Witold Bańka is a Polish former 400 metres sprinter turned politician. Since 2015, he served as Minister of Sport and Tourism in the cabinet of Beata Szydło and cabinet of Mateusz Morawiecki. In May 2019, he was elected President of the World Anti-Doping Agency (WADA).
Systematic doping of Russian athletes has resulted in 51 Olympic medals stripped from Russia, four times the number of the next highest, and more than 30% of the global total. Russia has the most competitors who have been caught doping at the Olympic Games in the world, with more than 150.
Kamila Valeryevna Valieva is a Russian figure skater. She is the 2021 Rostelecom Cup champion, the 2021 Skate Canada champion, the 2020 Junior World champion, the 2019-20 Junior Grand Prix Final champion and the 2021 Russian national silver medalist.
Doping in figure skating involves the use of illegal performance-enhancing drugs (PEDs), specifically those listed and monitored by the World Anti-Doping Agency (WADA). Figure skaters occasionally have positive doping results but it is not common. Bans can be enforced on figure skaters by the International Skating Union (ISU) and each country's individual skating federation. These bans can often be career ending due to the competitive nature of figure skating. A ban may be revoked if it can be proved that the skater tested positive for a prescribed medication. Some figure skaters will use PEDs to help with recovery time, allowing them to train harder and longer. Figure skating is an aesthetic sport that combines both athleticism and artistic licence, where weight-loss substances will have little effect on athletic performance but skaters may be perceived as more graceful and sleek, which is required for an athlete to be competitive.
Figure skating at the 2022 Winter Olympics was held at the Capital Indoor Stadium in Beijing, China. The five events took place between 4 and 20 February 2022.
The 2022 Russian Figure Skating Championships were held from 21 to 26 December 2021 in Saint Petersburg. Medals were awarded in the disciplines of men's singles, women's singles, pairs, and ice dance. The results were among the criteria used to select Russia's teams to the 2022 European Championships and 2022 Winter Olympics.
The women's singles competition in figure skating at the 2022 Winter Olympics was held on 15 February and 17 February, at the Capital Indoor Stadium in Haidian District of Beijing. Anna Shcherbakova, representing the Russian Olympic Committee, won the event, and her teammate, Alexandra Trusova, the silver medal. Kaori Sakamoto of Japan won bronze. For all, it was their first individual Olympic medals; Sakamoto had earlier won a medal in the team event.
The team event in figure skating at the 2022 Winter Olympics was held on 4, 6, and 7 February, at the Capital Indoor Stadium in Haidian District of Beijing.
Sodium polydihydroxyphenylene thiosulfonate is under laboratory studies in Russia as a potential regulator of cell metabolism. It is purported to affect mitochondrial function, though this has not been proven in any high-quality, peer-reviewed publications.
The swimming competitions at the 2024 Summer Olympics in Paris were held from 27 July to 9 August 2024. Pool events took place at the Paris La Défense Arena, with the two-day marathon swimming staged at Pont Alexandre III through the Seine River.
↑ Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, etal. (September 2006). "A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure". J. Am. Coll. Cardiol. 48 (5): 992–998. doi:10.1016/j.jacc.2006.03.060. PMID16949492. S2CID46184701.
↑ Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, etal. (September 2008). "Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy". Circulation. 118 (12): 1250–1258. doi:10.1161/CIRCULATIONAHA.108.778019. PMID18765391. S2CID23580702.
↑ Howes, Laura (17 February 2022). "What is trimetazidine and why is it banned in Olympic competition?". cen.acs.org. Retrieved 2022-02-19. Trimetazidine (TMZ) is the generic name for the chemical that acts as a vasodilator and was discovered over 50 years ago (1970s). TMZ is commonly prescribed in Europe and Russia where it is taken as a pill or in delayed-release tablets to treat angina as well as vertigo, tinnitus, and certain visual disturbances. Since 2014, WADA has classed TMZ as a prohibited substance.
↑ Fragasso G, Rosano G, Baek SH, Sisakian H, Di Napoli P, Alberti L, etal. (March 2013). "Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study". International Journal of Cardiology. 163 (3): 320–325. doi:10.1016/j.ijcard.2012.09.123. PMID23073279.
Sellier P, Broustet JP (2003). "Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study". Am J Cardiovasc Drugs. 3 (5): 361–369. doi:10.2165/00129784-200303050-00007. PMID14728070. S2CID68895472.
Génissel P, Chodjania Y, Demolis JL, Ragueneau I, Jaillon P (2004). "Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers". Eur J Drug Metab Pharmacokinet. 29 (1): 61–68. doi:10.1007/BF03190575. PMID15151172. S2CID10455129.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
(what is this?) (verify) 
